Tourniquet Use in Primary TKA: No PROM Benefit but Reduced Blood Loss
The use of tourniquet in total knee arthroplasty does not impact the functional outcome: a randomised controlled study.
J Orthop Surg Res . 2024 Oct 30;19(1):704.Eighty-one patients with knee osteoarthritis scheduled for primary TKA were randomized to tourniquet (n=42) or no tourniquet (n=39). The primary outcome was FJS-12 at 8 weeks. Secondary outcomes included quadriceps/leg-press strength (1RM), active ROM, stair climb test, pain (NPRS), opioid use (MME), estimated peri-operative blood loss, haemoglobin fall, operative time, knee circumference, and length of stay; outcomes were assessed pre-op, Day 1, 8 weeks, and 1 year. Overall, the results revealed no between-group difference in FJS-12 at 8 weeks. However, tourniquet use improved knee-extension strength at 8 weeks and reduced estimated peri-operative blood loss and Hb fall; other outcomes, including LOS, were similar. These findings suggest tourniquet use does not change early joint awareness but confers haemostatic benefits and small early strength advantages without clear downsides in other measured domains.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics